NSCLC with squamous histology: Current treatment and new options on horizon
|
|
- Valerie Wilkerson
- 6 years ago
- Views:
Transcription
1 NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015
2 Lung Cancer: Incidence and Mortality New cases in 2013: 228,190 40% with stage IV disease at presentation (~ 90,000) ~ 160,000 deaths in 2012, comparable to prostate, pancreas, breast, and colon cancer combined 5-yr relative survival rate: 15.7 % overall; 3.7% for patients with distant-stage disease 180, , , , ,000 80,000 60,000 40,000 20,000 0 Estimated Cancer Deaths by Site, 2012 Prostate Pancreas Breast Colon Other Cancers Lung cancer Lung Cancer NCI. Non-small-cell lung cancer treatment (PDQ ). ACS. Cancer facts & figures: CDC. Lung cancer rates by race and ethnicity. Howlader N, et al. SEER cancer statistics review.
3 Cancer Incidence, % Histologic Subtypes of NSCLC Decreasing Incidence of Squamous Cell Subtype Over Time 10%-15% 20% Adenocarcinoma 25%-30% Squamous cell carcinoma Large cell carcinoma Other or not otherwise specified 40% 85% of lung cancers are NSCLC. American Cancer Society database. Available at: Accessed March 24, Incidence of Histologic Types: Males and Females Yr of Diagnosis (3-Yr Moving Average) Adenocarcinoma Squamous cell Large cell Wahbah M et al. Ann Diagn Pathol. 2007;11:89-96.
4 Histology in Management of Advanced- Stage Non Oncogene-Driven NSCLC What is the current treatment algorithm in the absence of a known and targetable oncogenic driver? Is NSCLC histologic subtype prognostic (ie, portends patient outcome independent of therapeutic intervention)? Is NSCLC histologic subtype predictive of differential benefit from available therapies? Adenocarcinoma Squamous Large Cell
5 Outcomes for Advanced Adenocarcinoma vs Squamous Cell NSCLC Recent OS gains more pronounced for patients with adenocarcinoma histology, less for patients with squamous cell tumors Period Overall Survival, 1 Yr vs 2 Yr, % HR*, P Value All (N = 129,337) 1 yr yr yr yr 7.8 Adenocarcinoma (n = 53,300) 1 yr yr yr yr 9.9 *Comparison uses adenocarcinoma data as reference. Squamous Cell (n = 22,944) 1 yr yr yr yr ; P = ; P =.02 Adapted from Morgensztern D, et al. J Thor Oncol. 2009;4:
6
7
8
9 Retrospective Analysis of ECOG 1594 by Histology Squamous (n=224) Adenocarcinoma (n=647) Large Cell (n=74) Other (n=194) Regimen Median 95% C1 Median 95% C1 Median 95% C1 Median 95% C1 p- value CP 6.9 (5.3, 9.4) 9.1 (7.9, 10.9) 6.1 (2.9, inf) 6 (3.9, 9.1) 0.09 CG 9.4 (5.7, 15.5) 8.1 (6.8, 9.8) 9.7 (4.5, 17.1) 7.9 (6.3, 11.3) 0.63 OS (mo) CD 8.1 (5.5, 11.2) 7.7 (6.5, 9.4) , (5.6, 12.4) 0.01 CbP 9.3 (7.3, 12.1) 7.6 (6.6, 9.8) 8.3 (3.6, 16.7) 6.9 (4.9, 11.6) 0.37 p-value CP 2.6 (1.7, 4.2) 3.7 (3.1, 4.3) 3.5 (1.4, inf) 2.8 (1.8, 4.0) 0.43 CG 4.1 (3.3, 6.6) 4.4 (3.8, 5.4) 4.5 (2.0, 11.5) 3.4 (2.8, 5.1) 0.43 PFS (mo) CD 3.1 (2.4, 5.0) 3.7 (2.6, 4.6) 4.2 (2.0, 6.6) 3.6 (2.7, 5.6) 0.54 CbP 3.7 (3.0, 5.0) 3.5 (2.9, 4.2) , 7.8) , 3.9) 0.25 p-value Histological subtypes did not influence overall survival and progression free survival in chemonaïve patients treated with platinum-based doublets involving paclitaxel, docetaxel or gemcitabine Tien H et al. J Thorac Oncol 4:S493, 2009
10 Phase III nab-p/c vs P/C Study Design Socinski MA et al. ASCO 2010, LBA# 7511 Chemo-naive PS 0-1 Stage IIIb/IV NSCLC N = 1,050 Stratification factors: Stage (IIIb vs IV) Age (<70 vs >70) Sex Histology (squamous vs nonsquamous) Geographic region 1:1 nab-paclitaxel 100 mg/m 2 d1, 8, 15 Carboplatin AUC 6 d1 No Premedication n = 525 Paclitaxel 200 mg/m 2 d1 Carboplatin AUC 6 d1 With Premedication of Dexamethasone + Antihistamines n = 525
11 Results: Baseline Demographics nab-p/c (n = 521) P/C (n = 531) All Patients (N = 1052) Age, median (range) years 60 (28, 81) 60 (24, 84) 60 (24, 84) <70 years, n (%) 70 years, n (%) 448 (86) 73 (14) 449 (85) 82 (15) 897 (85) 155 (15) Female, n (%) 129 (25) 134 (25) 263 (25) ECOG, n (%) (26) 113 (21) 246 (23) (74) 416 (78) 801 (76) Histology of Primary Diagnosis, n (%)* Adenocarcinoma 254 (49) 264 (50) 518 (49) Squamous Cell Carcinoma 228 (44) 221 (42) 449 (43) Large Cell Carcinoma 9 (2) 13 (2) 22 (2) Other 29 (6) 33 (6) 62 (6) Stage at Current Diagnosis, n (%)* Stage III 99 (19) 107 (20) 206 (20) Stage IV 421 (81) 424 (80) 845 (80) Prior Chemotherapy, n (%) 12 (2) 8 (2) 20 (2) Smoking Status, n (%) Never Smoked 138 (27) 144 (28) 282 (27) Smoked and Quit 165 (32) 146 (28) 311 (30) Smoked and Still Smokes 210 (41) 231 (44) 441 (43) *Data was missing for 1 pt at the time of this analysis
12 Percent Responses Objective Responses by Histology Squamous Nonsquamous P < P = P = P = % nab-p/c 40% 30% 20% 41% 24% 37% 29% 26% 25% 37% 30% P/C 10% 0% Independent Radiologic Review Investigator Assessment Independent Radiologic Review Investigator Assessment n = 228 n = 221 n = 292 n = 310 Socinski MA et al. ASCO 2010 #7511
13 Exploratory Overall Survival Analysis in Selected Strata Carboplatin/ paclitaxel Carboplatin/ nab paclitaxel Hazard ratio p-value Squamous (n = 221, 229) 9.5 months 10.7 months * Age 70 years (n = 82, 74) 10.4 months 19.9 months * * Subgroup analyses exploratory in nature
14 Targeted Agents in Squamous cell Carcinoma
15 Trial Outcome with Targeted Agents in Squamous Cell CA Agent Trial Results Bevacizumab Phase II Associated with increased risk of severe pulmonary hemorrhage (4/13 pts) Sorafenib Phase III ESCAPE Increased risk of death Motesanib Phase III MONET Increased risk of hemoptysis Cediranib Phase II BR24 No increased toxicity or efficacy Figitumumab Phase III No histology specific findings but ADVIGO (2) increased toxicity and no benefit Cetuximab Phase III FLEX No histology specific findings
16 FLEX: Phase III Evaluation of Cetuximab Plus Chemotherapy Advanced-stage, previously untreated NSCLC patients with EGFR+ in 1 tumor cell and no brain metastases (N = 1125) Cisplatin 80 mg/m 2 on Day 1 Vinorelbine 25 mg/m 2 on Days 1 and 8 Six 3-wk cycles Cetuximab 400 mg/m 2 over 2 hrs on Day mg/m 2 over 1 hr wkly from Day 8 Continued until disease progression Cisplatin 80 mg/m 2 on Day 1 Vinorelbine 25 mg/m 2 on Days 1 and 8 Six 3-wk cycles Primary endpoint: OS Secondary endpoints: PFS, RR, QoL, safety Pirker R, et al. Lancet. 2009;373:
17 FLEX: Efficacy Outcomes Outcome Cisplatin/ Vinorelbine + Cetuximab (n = 557) Cisplatin/ Vinorelbine (n = 568) HR (95% CI) Median OS, mos ( ) Median PFS, mos ( ) Median TTF, mos ( ) P Value Response rate, % Pirker R, et al. Lancet. 2009;373:
18 OS (%) FLEX: Cetuximab + Chemotherapy vs Chemotherapy in Advanced NSCLC Significant OS benefit for addition of cetuximab to cisplatin/vinorelbine 100 Chemotherapy + cetuximab 80 Chemotherapy HR: (95% CI: ; P =.044) Mos Patients at Risk, n Chemotherapy cetuximab Chemotherapy Pirker R, et al. Lancet. 2009;373:
19 OS (%) OS (%) FLEX Study: OS by Histology in Patients with High EGFR Expression 100 Adenocarcinoma (N = 135) Squamous (N = 144) Survival Survival Median, Mos 1 Yr, % Median, Mos 1 Yr, % CT + cetuximab CT + cetuximab CT CT HR: 0.74 (95% CI: ) 80 HR: 0.62 (95% CI: ) Time (Mos) Time (Mos) Pirker R, et al. IASLC Abstract 1557.
20 SQUIRE: Chemotherapy +/- Necitumumab for First Line Adv. Squamous NSCLC Necitumumab (Neci) (IMC-11F8) is a human IgG1 anti-egfr monoclonal antibody Adv. squamous NSCLC Treatment-naïve N = 1093 Primary endpoint: OS R A N D O M I Z E Cisplatin/Gemcitabine + Necitumumab up to 6 cycles Cisplatin/Gemcitabine up to 6 cycles Cisplatin 75 mg/m2 IV day 1 q21 days Gemcitabine 1250 mg/m2 IV days 1, 8 q21 days Necitumumab 800 mg/kg IV days 1, 8 q21 days Maintenance neci until progression Thatcher, A#8008
21 SQUIRE: Efficacy of Necitumumab Chemo/Neci (N = 545) Chemo alone (N = 548) ORR (CR + PR) 31.2% 28.8% DCR (CR + PR +SD) 81.8% 77.0% 0.043* P Progression-Free Survival (ITT) *Cochran-Mantel-Haenszel test (stratified) Overall Survival (ITT) Thatcher, A#8008
22 SQUIRE: Toxicity of Necitumumab Thatcher, A#8008
23 SQUIRE: FLEX Redux? (Re-FLEX?) SQUIRE FLEX Thatcher, A#8008 Pirker, Lancet 2009 Extremely similar agent; extremely similar results. Cetuximab has had negligible impact on NSCLC management Highlights distinction between statistical & clinical significance
24 Place of Maintenance in S.C.C.? SATURN (old) ABOUND (new)
25 SATURN study design Chemonaïve advanced NSCLC n=1,949 Mandatory tumour sampling 4 cycles of firstline platinum doublet chemotherapy* Non-PD n=889 Erlotinib 150mg/day Placebo PD PD Stratification factors: EGFR IHC (positive vs negative vs indeterminate) Stage (IIIB vs IV) ECOG PS (0 vs 1) CT regimen (cis/gem vs carbo/doc vs others) Smoking history (current vs former vs never) Region Co-primary endpoints: PFS in all patients PFS in patients with EGFR IHC+ tumours Secondary endpoints: OS in all patients and those with EGFR IHC+ tumours, OS and PFS in EGFR IHC tumours; biomarker analyses; safety; time to symptom progression; QoL *Cisplatin/paclitaxel; cisplatin/gemcitabine; cisplatin/docetaxel cisplatin/vinorelbine; carboplatin/gemcitabine; carboplatin/docetaxel carboplatin/paclitaxel Future Oncology, December 2010, Vol. 6, No. 12, Pages
26 PFS according to histology Adenocarcinoma Squamous-cell carcinoma PFS probability PFS probability 1.0 HR=0.60 ( ) 1.0 HR=0.76 ( ) 0.8 Log-rank p< Log-rank p= Erlotinib (n=204) Placebo (n=197) 0.4 Erlotinib (n=166) Placebo (n=193) Time (weeks) Time (weeks) Future Oncology, December 2010, Vol. 6, No. 12, Pages
27
28 NEW COMER Ramucirumab
29
30
31
32
33
34
35 Breakthrough of the year Couzin-Frankel. Science 2013 Hanahan & Weinberg. Cell 2011
36 PD-L1 is expressed in many solid tumours PD-L1 is broadly expressed by tumour cells and tumour-infiltrating immune cells PD-L1 prevalence 1 3 Tumour type Non-trial study 1,2 * (immune cell), % Phase I study3 Immune Tumour cell cell* NSCLC 45% 26% 24% RCC 20% 25% 10% PD-L1+ immune cells (NSCLC) 1 Melanoma 40% 36% 5% Bladder 4 N/A 27% 11% HNSCC 33% 28% 19% Gastric cancer N/A 18% 5% CRC 45% 35% 1% Pancreatic cancer N/A 12% 4% PD-L1+ tumour cells (melanoma) 1 PD-L1 expression assessed with proprietary Genentech/Roche IHC reagent *PD-L1+ defined as patients with 5% tumour infiltrating immune cells positive for PD-L1 Surgical tumour specimens; PD-L1-positive defined as patients with 5% tumour cells positive for PD-1 1. Kohrt, et al. 2013; 2. Roche/Genentech data; 3. Herbst, et al. 2014; 4. Powles, et al. 2014
37 Overview of several anti-pdl1/pd1 therapies currently in development Therapies are currently in development that target both PD-L1 and PD-1 Therapeutic Lead company Antibody type Affinity/K 2 * Reference Anti-PDL1 MPDL3280A MEDI-4736 BMS Anti-PD1 Nivolumab MK3475 (pembrolizumab) AMP-224 Roche AstraZeneca Bristol-Myers Squibb Bristol-Myers Squibb Engineered IgG1 (no ADCC) Modified IgG1 (no ADCC) IgG4 IgG4 0.4nM Not available Not available 2.6nM Merck & Co IgG4 (humanised) 29pM GlaxoSmithKline PD-L2 IgG1 Fc fusion Not available Herbst, et al. ASCO 2013 Stewart, et al. Cancer Res 2011 Brahmer, et al. NEJM 2012 Brahmer, et al. J Clin Oncol 2010 Patnaik, et al. J Clin Oncol 2012 Smothers, et al. Ann Oncol 2013 *Affinity/K 2 describes the strength of binding of an antibody to PD-L1 or PD-1; the lower the value, the higher the affinity
38 Current Players OPDIVO Atezolizumab KEYTRUDA
39 NIVOLUMAB Story in Checkmate-017 Checkmate-063 (label trial) Checkmate-057
40 *July 2014 database lock Ramalingam, et al. 2014
41 *July 2014 database lock Ramalingam, et al. 2014
42 CheckMate 017: study design Stage IIIB/IV NSCLC Squamous histology Nivolumab 3mg/kg IV q2w (n=135) 1 prior line of platinum doubletbased chemotherapy Pre-treatment (archival or fresh) tumour samples required for PD-L1 analysis R 1:1 PD ECOG PS 0 1 (n=272) Docetaxel 75mg/m 2 IV q3w (n=137) Primary endpoint OS Secondary endpoints Investigator assessed ORR Investigator assessed PFS Correlation between PD-L1 expression and efficacy Safety Quality of life (LCSS) NCT Spigel, et al. ASCO 2015 (updated data from congress presentation)
43 CheckMate 017: baseline characteristics Nivolumab (n=135) Docetaxel (n=137) Median age (range), years 62 (39 85) 64 (42 84) Age category: 75 years, % 8 13 Male, % Disease stage: IIIB / IV, % 21 / / 82 PS 0 / 1, % 20 / / 73 CNS metastasis, % 7 6 Prior paclitaxel, % Current or former smoker, % PD-L1 expression:* 1% / 5% / 10% / not quantifiable 47 / 31 / 27 / / 29 / 24 / 21 83% (225/272) of patients had quantifiable PD-L1 expression *Percentage of all randomised patients NCT Spigel, et al. ASCO 2015 (updated data from congress presentation)
44 OS estimate CheckMate 017: OS (updated) mos, months (95% CI) Nivolumab (n=135) 9.2 ( ) Docetaxel (n=137) 6.0 ( ) Number of events HR 0.62 ( ) p= month OS rate = 42% 18-month OS rate = 28% Nivolumab Docetaxel month OS rate = 24% 18-month OS rate = 13% 0 0 Minimal follow-up for survival: 18 months Based on August 2015 database lock Symbols refer to censored observations HR = hazard ratio Time (months) NCT Reckamp, et al WCLC 2015; Reck, et al. ECC 2015; Gralla, et al. WCLC 2015 (updated data from congress presentation)
45 PFS estimate CheckMate 017: PFS (updated) mpfs, months (95% CI) Nivolumab (n=135) 3.5 ( ) Docetaxel (n=137) 2.8 ( ) Number of events HR 0.63 ( ) p= Nivolumab Docetaxel month PFS rate = 21% 18-month PFS rate = 17% 0 0 Minimal follow-up for survival: 18 months Based on August 2015 database lock Symbols refer to censored observations 12-month PFS rate = 6.4% Time (months) 18-month PFS rate = 2.7% NCT Reckamp, et al WCLC 2015 (updated data from congress presentation)
46 CheckMate 017: survival benefit by PD-L1 expression PD-L1 expression OS PFS <1% 1% <5% 5% <10% 10% Nivo n Doc n HR (95% CI) 0.58 ( ) 0.69 ( ) 0.70 ( ) 0.53 ( ) 0.70 ( ) 0.50 ( ) Not quantifiable ( ) <1% 1% <5% 5% <10% 10% ( ) 0.67 ( ) 0.75 ( ) 0.54 ( ) 0.70 ( ) 0.58 ( ) Not quantifiable ( ) Interaction p-value Favours nivolumab Favours docetaxel Nivolumab benefit was independent of PD-L1 expression PD-L1 positive expression HR PD-L1 negative expression Not quantifiable 83% of patients (225/272) had quantifiable PD-L1 expression Based on December 2014 database lock CI = confidence intervals NCT Reckamp, et al WCLC 2015 (updated data from congress presentation)
47 CheckMate 017: Conclusions With longer follow-up, nivolumab continues to demonstrate OS and PFS benefit compared with docetaxel in previously treated patients with advanced squamous cell NSCL 41% reduction in risk of death (HR=0.59; p= ) 1-yr OS: 42% vs 24% 18-month OS (28% vs 13%) and PFS (17% vs 2.7%) mos: 9.2 vs 6.0 months (HR=0.62; p=0.0004) Nivolumab demonstrated superiority over docetaxel across all secondary efficacy endpoints ORR: 20% vs 9% (p=0.0083) 1-yr PFS: 21% vs 6.4%; mpfs 3.5 vs 2.8 months (HR=0.62; p=0.0004) Nivolumab benefit was independent of PD-L1 expression NCT Reck, et al. ECC 2015; Gralla, et al. WCLC 2015; Reckamp, et al WCLC 2015 (updated data from congress presentation) NCT Spigel, et al. ASCO 2015 (updated data from congress presentation)
48 PEMBROLIZUMAB(KEYTRUDA) Keynote-001 Keynote-010 Keynote-024 Keynote-042
49 KEYNOTE-001: study design Locally-advanced or metastatic disease Carcinoma, melanoma, NSCLC Pembrolizumab in chemo-naïve patients with PD-L1+ NSCLC (n=101) 2mg/kg q3w 10mg/kg q2w 10mg/kg q3w NSCLC: EGFR Mut+ or ALK+ permitted in previously-treated patients (with PD on relevant TKI) but not for treatment-naïve patients ECOG PS 0 1 (n=1,137 all tumour types) Pembrolizumab in previously treated NSCLC (n=449) 18%SCC 2L 3L 10mg/kg q2w; PD-L1 (n=43) 2mg/kg q3w; PD-L1+ (n=55) randomized 3:2 to 10mg/kg q2w or q3w; PD-L1+ (n=280) 10mg/kg q3w; PD-L1+ or PD- L1 (n=38) 10mg/kg q3w; PD-L1+ (n=33) Primary endpoint DLTs AEs Response rate Biomarker expression Secondary endpoints Pharmacokinetics PFS OS DoR *PD-L1+ defined as 1% tumour PD-L1 expression by central IHC assay using the 22C3 antibody AEs = adverse events; DLTs = dose-limiting toxicities; DoR = duration of response ECOG PS = Eastern Cooperative Oncology Group performance status EGFR = epidermal growth factor receptor; OS = overall survival; PD = progressive disease PD-L1 = programmed death-ligand 1; PFS = progression-free survival; TKI = tyrosine kinase inhibitor NCT Soria, et al. ECC 2015 (updated data from congress presentation)
50 KEYNOTE-001: Conclusions Efficacy and safety were similar across 2 mg/kg and 10 mg/kg doses of pembrolizumab, supporting 2 mg/kg q3w as an effective dose in NSCLC PD-L1 TPS(Tissue polyppteptide specificic antigen) 50% identifies patients with greatest likelihood of clinical benefit patients with higher PD-L1 expression may have a faster time to response Additional data will be provided by the ongoing randomised KEYNOTE-010 study (NCT ) of pembrolizumab at 2mg/kg or 10mg/kg versus docetaxel NCT Soria, et al. ECC 2015 (updated data from congress presentation)
51
52 Atezolizumab POPLAR BIRCH
53
54
55
56
57 POPLAR summary The POPLAR Phase II randomized study demonstrated significant improvements in OS for unselected NSCLC patients receiving atezolizumab vs docetaxel ITT: OS HR = 0.73 (P =.040) Higher PD-L1 expression associated with improved overall survival with atezolizumab Activity was observed in both squamous and non-squamous NSCLC patients treated with atezolizumab Atezolizumab was well tolerated with a safety profile consistent with previous studies,distinct from chemotherapy
58 (28%SCC)
59
60 Cancer immunotherapy: induction of longterm survival future Direction...Combination??!! Overall survival Combinations Checkpoint inhibitors Chemotherapy 60
61
62 Pembrolizumab
63 Where to go and How to Follow in Advanced NSCLC(Sq.Cell Ca) 2015?
64 Current Treatment Guidelines for Metastatic NSCLC (2015)
65 Current Treatment Guidelines for Metastatic NSCLC (2015)
66 Take Home Messages
67 We are rapidly moving from Clinical to Biological Predictors in NSCLC Treatment Algorithms in 2015.
68
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationRecent Therapeutic Advances in Squamous Cell Carcinoma of the Lung
Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung 2017 Conversations in Oncology in Shanghai, China Prof. Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital Affiliated to Medical
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationCarcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer June 3, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer June 3, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More information